A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results

被引：1

作者：

Richardson, Paul G. ^{[1
]}

Jagannath, Sundar ^{[2
]}

Moreau, Philippe ^{[3
]}

Jakubowiak, Andrzej ^{[4
]}

Raab, Marc S. ^{[5
,6
]}

Facon, Thierry ^{[7
]}

Vij, Ravi ^{[8
]}

White, Darrell J. ^{[9
]}

Reece, Donna ^{[10
]}

Benboubker, Lotfi ^{[11
]}

Zonder, Jeffrey A. ^{[12
]}

Deng, Wei ^{[13
]}

Kroog, Glenn ^{[14
]}

Singhal, Anil K. ^{[13
]}

Lonial, Sagar ^{[15
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Mt Sinai Med Ctr, New York, NY 10029 USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] Heidelberg Univ, Med Ctr, Heidelberg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] Hop Claude Huriez, Serv Malad Sang, Lille, France

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Queen Elizabeth 2 Hlth Sci Ctr, Div Hematol, Halifax, NS, Canada

[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[11] Hop Bretonneau, Ctr Reg Cancerol Henry Kaplan CHRU Tours, Serv Hematol & Therapies Cellulaires, Tours, France

[12] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[13] Abbott Biotherapeut Corp, Redwood City, CA USA

[14] Bristol Myers Squibb Co, Princeton, NJ USA

[15] Emory Univ, Div BMT, Winship Canc Inst Hematol & Med Oncol, Atlanta, GA 30322 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

202

引用

页数：2

共 50 条

[1] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Lonial, Sagar
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Moreau, Philippe
Reece, Donna E.
White, Darrell J.
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn
Singhal, Anil K.
Richardson, Paul G.
BLOOD, 2011, 118 (21) : 141 - 142
[2] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Moreau, Philippe
Mazumder, Amitabha
Kaufman, Jonathan L.
Leleu, Xavier
Tsao, L. Claire
Westland, Christopher
Singhal, Anil K.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
[3] Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Moreau, Philippe
Leleu, Xavier
Mazumder, Amitabha
Kaufman, Jonathan L.
Westland, Christopher E.
Tsao, Claire
Singhal, Anil K.
Jagannath, Sundar
BLOOD, 2010, 116 (21) : 805 - 806
[4] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Moreau, P.
Richardson, P.
Jakubowiak, A.
Jagannath, S.
Raab, M.
Facon, T.
Vij, R.
Reece, D.
White, D.
Benboubker, L.
Zonder, J.
Rossi, J. F.
Tsao, C.
Parli, T.
Kroog, G.
Singhal, A.
Lonial, S.
HAEMATOLOGICA, 2012, 97 : 474 - 474
[5] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
Lonial, S.
Vij, R.
Harousseau, J.
Facon, T.
Moreau, P.
Leleu, X.
Westland, C.
Singhal, A. K.
Jagannath, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
Lonial, S.
Vij, R.
Harousseau, J. L.
Facon, T.
Moreau, P.
Mazumder, A.
Kaufman, J.
Leleu, X.
Tsao, C.
Fry, J.
Singhal, A.
Jagganath, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
[7] Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results
Lonial, Sagar
Vij, Ravi
Harousseau, Jean-Luc
Facon, Thierry
Kaufman, Jonathan
Mazumder, Amitabha
Moreau, Philippe
Leleu, Xavier
Fry, John
Singhal, Anil
Jagannath, Sundar
BLOOD, 2009, 114 (22) : 179 - 180
[8] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
Moreau, Philippe
Richardson, Paul Gerard Guy
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc
Facon, Thierry
Vij, Ravi
Reece, Donna Ellen
White, Darrell
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn Scott
Singhal, Anil
Lonial, Sagar
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[9] Final results for the 1703 phase 1b/2 study of Elotuzumab (Elo) in combination with Lenalidomide (Len) and dexamethasone (dex) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Raab, M. S.
Richardson, P. G.
Jagannath, S.
Moreau, P.
Jakubowiak, A. J.
Facon, T.
Vij, R.
White, D.
Reece, D. E.
Benboubker, L.
Zonder, J.
Tsao, L. C.
Anderson, K. C.
Bleickardt, E.
Singhal, A. K.
Lonial, S.
Oncology Research and Treatment, 2015, 38 : 165 - 165
[10] Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study
Richardson, Paul G.
Moreau, Philippe
Jakubowiak, Andrzej J.
Facon, Thierry
Jagannath, Sundar
Vij, Ravi
Reece, Donna E.
White, Darrell J.
Raab, Marc S.
Benboubker, Lotfi
Rossi, Jean-Francois
Tsao, Claire
Fry, John
Berman, David
Singhal, Anil K.
Lonial, Sagar
BLOOD, 2010, 116 (21) : 434 - 434

← 1 2 3 4 5 →